Encapsulating peritoneal sclerosis: Prevention and treatment

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Kawanishi, Hideki ^a   Moriishi, Misaki ^a  

^a TSUCHIYA GENERAL HOSPITAL   (Japan)

Author keywords

Encapsulating peritoneal sclerosis; EPS; Peritoneal deterioration; Surgical options

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISOLONE; STEROID;

CLINICAL PROTOCOL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DRUG USE; HUMAN; INCIDENCE; INTESTINE OBSTRUCTION; LAPAROTOMY; LOW DRUG DOSE; MONITORING; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEAL SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION;

COMBINED MODALITY THERAPY; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PERITONEAL DISEASES; RISK FACTORS; SCLEROSIS;

EID: 35748973278     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. international Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S43-55.
2. Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H, et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25(Suppl 4):S83-95.
3. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14-27.
4. Kawanishi H, Harada Y, Noriyuki T, Kawai T, Takahashi S, Moriishi M, et al. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 2001; 17:200-4.
5. Nakayama M, Yamamoto H, Ikeda M, Hasegawa T, Kato N, Takahashi H, et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis - Jikei experience 2002. Adv Perit Dial 2002; 18:144-8.
6. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous peritoneal dialysis. A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420-7.
7. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13:154-9.
8. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan; prospective multicenter survey, Am J Kidney Dis 2004; 44: 729-37.
9. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
10. Moriishi M, Kawanishi H, Kawai T, Takahashi S, Hirai T, Shishida M, et al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial 2002; 18:149-53.
11. Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9:187-9.
12. Kawanishi H, Moriishi M, Tsuchiya S. Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. Adv Perit Dial 2006; 22:60-4.
13. Numata M, Nakayama M, Nimura S, Kawakami M, Lindholm B, Kawaguchi Y. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23:116-22.